The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial

T. I. Chang, S. Abdalla, G. M. London, G. A. Block, R. Correa-Rotter, T. B. Drüeke, J. Floege, C. A. Herzog, K. W. Mahaffey, Sharon Moe, P. S. Parfrey, D. C. Wheeler, B. Dehmel, W. G. Goodman, G. M. Chertow

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which may contribute to the high prevalence of arterial stiffness and hypertension. We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, in which patients receiving hemodialysis with sHPT were randomly assigned to receive cinacalcet or placebo. We sought to examine whether the effect of cinacalcet on death and major cardiovascular events was modified by baseline pulse pressure as a marker of arterial stiffness, and whether cinacalcet yielded any effects on blood pressure. As reported previously, an unadjusted intention-to-treat analysis failed to conclude that randomization to cinacalcet reduces the risk of the primary composite end point (all-cause mortality or non-fatal myocardial infarction, heart failure, hospitalization for unstable angina or peripheral vascular event). However, after prespecified adjustment for baseline characteristics, patients randomized to cinacalcet experienced a nominally significant 13% lower adjusted risk (95% confidence limit 4-20%) of the primary composite end point. The effect of cinacalcet was not modified by baseline pulse pressure (Pinteraction = 0.44). In adjusted models, at 20 weeks cinacalcet resulted in a 2.2 mm Hg larger average decrease in systolic blood pressure (P=0.002) and a 1.3 mm Hg larger average decrease in diastolic blood pressure (P=0.002) compared with placebo. In summary, in the EVOLVE trial, the effect of cinacalcet on death and major cardiovascular events was independent of baseline pulse pressure.

Original languageEnglish (US)
Pages (from-to)204-209
Number of pages6
JournalJournal of Human Hypertension
Volume30
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Blood Pressure
Mortality
Vascular Stiffness
Secondary Hyperparathyroidism
Placebos
Cinacalcet Hydrochloride
Intention to Treat Analysis
Unstable Angina
Random Allocation
Phosphorus
Chronic Kidney Failure
Blood Vessels
Renal Dialysis
Hospitalization
Homeostasis
Heart Failure
Myocardial Infarction
Hypertension
Calcium

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Chang, T. I., Abdalla, S., London, G. M., Block, G. A., Correa-Rotter, R., Drüeke, T. B., ... Chertow, G. M. (2016). The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. Journal of Human Hypertension, 30(3), 204-209. https://doi.org/10.1038/jhh.2015.56

The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. / Chang, T. I.; Abdalla, S.; London, G. M.; Block, G. A.; Correa-Rotter, R.; Drüeke, T. B.; Floege, J.; Herzog, C. A.; Mahaffey, K. W.; Moe, Sharon; Parfrey, P. S.; Wheeler, D. C.; Dehmel, B.; Goodman, W. G.; Chertow, G. M.

In: Journal of Human Hypertension, Vol. 30, No. 3, 01.03.2016, p. 204-209.

Research output: Contribution to journalArticle

Chang, TI, Abdalla, S, London, GM, Block, GA, Correa-Rotter, R, Drüeke, TB, Floege, J, Herzog, CA, Mahaffey, KW, Moe, S, Parfrey, PS, Wheeler, DC, Dehmel, B, Goodman, WG & Chertow, GM 2016, 'The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial', Journal of Human Hypertension, vol. 30, no. 3, pp. 204-209. https://doi.org/10.1038/jhh.2015.56
Chang, T. I. ; Abdalla, S. ; London, G. M. ; Block, G. A. ; Correa-Rotter, R. ; Drüeke, T. B. ; Floege, J. ; Herzog, C. A. ; Mahaffey, K. W. ; Moe, Sharon ; Parfrey, P. S. ; Wheeler, D. C. ; Dehmel, B. ; Goodman, W. G. ; Chertow, G. M. / The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial. In: Journal of Human Hypertension. 2016 ; Vol. 30, No. 3. pp. 204-209.
@article{8101dfa6eee34032b041e11a1a58ff8f,
title = "The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial",
abstract = "Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which may contribute to the high prevalence of arterial stiffness and hypertension. We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, in which patients receiving hemodialysis with sHPT were randomly assigned to receive cinacalcet or placebo. We sought to examine whether the effect of cinacalcet on death and major cardiovascular events was modified by baseline pulse pressure as a marker of arterial stiffness, and whether cinacalcet yielded any effects on blood pressure. As reported previously, an unadjusted intention-to-treat analysis failed to conclude that randomization to cinacalcet reduces the risk of the primary composite end point (all-cause mortality or non-fatal myocardial infarction, heart failure, hospitalization for unstable angina or peripheral vascular event). However, after prespecified adjustment for baseline characteristics, patients randomized to cinacalcet experienced a nominally significant 13{\%} lower adjusted risk (95{\%} confidence limit 4-20{\%}) of the primary composite end point. The effect of cinacalcet was not modified by baseline pulse pressure (Pinteraction = 0.44). In adjusted models, at 20 weeks cinacalcet resulted in a 2.2 mm Hg larger average decrease in systolic blood pressure (P=0.002) and a 1.3 mm Hg larger average decrease in diastolic blood pressure (P=0.002) compared with placebo. In summary, in the EVOLVE trial, the effect of cinacalcet on death and major cardiovascular events was independent of baseline pulse pressure.",
author = "Chang, {T. I.} and S. Abdalla and London, {G. M.} and Block, {G. A.} and R. Correa-Rotter and Dr{\"u}eke, {T. B.} and J. Floege and Herzog, {C. A.} and Mahaffey, {K. W.} and Sharon Moe and Parfrey, {P. S.} and Wheeler, {D. C.} and B. Dehmel and Goodman, {W. G.} and Chertow, {G. M.}",
year = "2016",
month = "3",
day = "1",
doi = "10.1038/jhh.2015.56",
language = "English (US)",
volume = "30",
pages = "204--209",
journal = "Journal of Human Hypertension",
issn = "0950-9240",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - The effects of cinacalcet on blood pressure, mortality and cardiovascular endpoints in the EVOLVE trial

AU - Chang, T. I.

AU - Abdalla, S.

AU - London, G. M.

AU - Block, G. A.

AU - Correa-Rotter, R.

AU - Drüeke, T. B.

AU - Floege, J.

AU - Herzog, C. A.

AU - Mahaffey, K. W.

AU - Moe, Sharon

AU - Parfrey, P. S.

AU - Wheeler, D. C.

AU - Dehmel, B.

AU - Goodman, W. G.

AU - Chertow, G. M.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which may contribute to the high prevalence of arterial stiffness and hypertension. We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, in which patients receiving hemodialysis with sHPT were randomly assigned to receive cinacalcet or placebo. We sought to examine whether the effect of cinacalcet on death and major cardiovascular events was modified by baseline pulse pressure as a marker of arterial stiffness, and whether cinacalcet yielded any effects on blood pressure. As reported previously, an unadjusted intention-to-treat analysis failed to conclude that randomization to cinacalcet reduces the risk of the primary composite end point (all-cause mortality or non-fatal myocardial infarction, heart failure, hospitalization for unstable angina or peripheral vascular event). However, after prespecified adjustment for baseline characteristics, patients randomized to cinacalcet experienced a nominally significant 13% lower adjusted risk (95% confidence limit 4-20%) of the primary composite end point. The effect of cinacalcet was not modified by baseline pulse pressure (Pinteraction = 0.44). In adjusted models, at 20 weeks cinacalcet resulted in a 2.2 mm Hg larger average decrease in systolic blood pressure (P=0.002) and a 1.3 mm Hg larger average decrease in diastolic blood pressure (P=0.002) compared with placebo. In summary, in the EVOLVE trial, the effect of cinacalcet on death and major cardiovascular events was independent of baseline pulse pressure.

AB - Patients with end-stage renal disease often have derangements in calcium and phosphorus homeostasis and resultant secondary hyperparathyroidism (sHPT), which may contribute to the high prevalence of arterial stiffness and hypertension. We conducted a secondary analysis of the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial, in which patients receiving hemodialysis with sHPT were randomly assigned to receive cinacalcet or placebo. We sought to examine whether the effect of cinacalcet on death and major cardiovascular events was modified by baseline pulse pressure as a marker of arterial stiffness, and whether cinacalcet yielded any effects on blood pressure. As reported previously, an unadjusted intention-to-treat analysis failed to conclude that randomization to cinacalcet reduces the risk of the primary composite end point (all-cause mortality or non-fatal myocardial infarction, heart failure, hospitalization for unstable angina or peripheral vascular event). However, after prespecified adjustment for baseline characteristics, patients randomized to cinacalcet experienced a nominally significant 13% lower adjusted risk (95% confidence limit 4-20%) of the primary composite end point. The effect of cinacalcet was not modified by baseline pulse pressure (Pinteraction = 0.44). In adjusted models, at 20 weeks cinacalcet resulted in a 2.2 mm Hg larger average decrease in systolic blood pressure (P=0.002) and a 1.3 mm Hg larger average decrease in diastolic blood pressure (P=0.002) compared with placebo. In summary, in the EVOLVE trial, the effect of cinacalcet on death and major cardiovascular events was independent of baseline pulse pressure.

UR - http://www.scopus.com/inward/record.url?scp=84958119489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958119489&partnerID=8YFLogxK

U2 - 10.1038/jhh.2015.56

DO - 10.1038/jhh.2015.56

M3 - Article

VL - 30

SP - 204

EP - 209

JO - Journal of Human Hypertension

JF - Journal of Human Hypertension

SN - 0950-9240

IS - 3

ER -